EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

Xiaoliang Yu, Haikuo Ma, Bohan Li iD, Yuting Ji, Yayun Du, Siying Liu, Zhanhui Li, Yongjin Hao, Sheng Tian, Cong Zhao, Qian Du, Zhongqin Jin und 22 weitere

Blood · 2023

DOI: 10.1182/blood.2022017262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Xiaoliang Yu und 33 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Synthetic Biology Regulatory Elements, Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical Co…. Hauptthemen laut MEDLINE: Intestines, Graft vs Host Disease. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intestinal epithelial cells (IECs) are implicated in the propagation of T-cell–mediated inflammatory diseases, including graft-versus-host disease (GVHD), but the underlying mechanism remains poorly defined. Here, we report that IECs require receptor-interacting protein kinase-3 (RIPK3) to drive both gastrointestinal (GI) tract and systemic GVHD after allogeneic hematopoietic stem cell transplantation. Selectively inhibiting RIPK3 in IECs markedly reduces GVHD in murine intestine and liver. IEC RIPK3 cooperates with RIPK1 to trigger mixed lineage kinase domain-like protein-independent production of T-cell–recruiting chemokines and major histocompatibility complex (MHC) class II molecules, which amplify and sustain alloreactive T-cell responses. Alloreactive T-cell–produced interferon gamma enhances this RIPK1/RIPK3 action in IECs through a JAK/STAT1-dependent mechanism, creating a feed-forward inflammatory cascade. RIPK1/RIPK3 forms a complex with JAK1 to promote STAT1 activation in IECs. The RIPK1/RIPK3-mediated inflammatory cascade of alloreactive T-cell responses results in intestinal tissue damage, converting the local inflammation into a systemic syndrome. Human patients with severe GVHD showed highly activated RIPK1 in the colon epithelium. Finally, we discover a selective and potent RIPK1 inhibitor (Zharp1-211) that significantly reduces JAK/STAT1-mediated expression of chemokines and MHC class II molecules in IECs, restores intestinal homeostasis, and arrests GVHD without compromising the graft-versus-leukemia (GVL) effect. Thus, targeting RIPK1/RIPK3 in IECs represents an effective nonimmunosuppressive strategy for GVHD treatment and potentially for other diseases involving GI tract inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IntestinesGraft vs Host DiseaseMiceHumansAnimalsIntestinal MucosaInflammationHistocompatibility Antigens Class IIHomeostasisReceptor-Interacting Protein Serine-Threonine Kinases

Substanzen

Histocompatibility Antigens Class IIReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRipk1 protein, mouse

Autor:innen und Institutionen

  • Key Laboratory of Synthetic Biology Regulatory Elements, Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Suzhou Institute of Systems Medicine, Suzhou, China.
  • Cyrus Tang Hematology Center and Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
  • Department of Hematology, Jiangsu Pediatric Center of Hematology & Oncology, and The Children's Hospital of Soochow University, Suzhou, China.
  • School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Bohan Li, Yuanyuan Tian, Haohao Lu, Xiaohu Zhang, Shaoyan Hu, Sudan He

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Yu, X., Ma, H., Li, B., Ji, Y., Du, Y., Liu, S., Li, Z., Hao, Y., Tian, S., Zhao, C., Du, Q., Jin, Z., Zhu, X., Tian, Y., Chen, X., Sun, X., Yang, C., Zhu, F., Ju, J., …, & He, S. (2023). A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis. Blood. https://doi.org/10.1182/blood.2022017262

Vancouver

Yu X, Ma H, Li B, Ji Y, Du Y, Liu S, et al. A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis. Blood. 2023. doi:10.1182/blood.2022017262

BibTeX
@article{Yu2023,
  author = {Yu, Xiaoliang and Ma, Haikuo and Li, Bohan and Ji, Yuting and Du, Yayun and Liu, Siying and Li, Zhanhui and Hao, Yongjin and Tian, Sheng and Zhao, Cong and Du, Qian and Jin, Zhongqin and Zhu, Xueming and Tian, Yuanyuan and Chen, Xin and Sun, Xue and Yang, Chengkui and Zhu, Fang and Ju, Jie and Zheng, Yunjing and Zhang, Wei and Wang, Jingrui and Yang, Tao and Wang, Xinhui and Li, Jingjing and Xu, Xiangping and Du, Shujing and Lu, Haohao and Ma, Feng and Zhang, Haibing and Zhang, Yi and Zhang, Xiaohu and Hu, Shaoyan and He, Sudan},
  title = {A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017262}
}
Kostenlos starten →